Fulgent Genetics Expands Reach with Two Big Buys

Fulgent Genetics is making a significant move in the lab industry. The company is acquiring Bako Diagnostics and StrataDx for a total of $55.5 million. The deal is expected to close in the first half of 2026, pending all necessary approvals.

A Strategic Move

Fulgent is renowned for its technology-driven approach to lab services and drug development. This acquisition will expand its test offerings and add expert teams to its portfolio.

• Bako Diagnostics brings a broad range of pathology services.
• StrataDx specializes in skin-related diagnostic tests.

Both companies are certified and accredited, ensuring they meet high industry standards.

Investing in Innovation

Fulgent is not only expanding through acquisitions but also investing in artificial intelligence and digital tools to enhance its services. With these new additions, Fulgent aims to offer more services and reach more customers across the country.

Leadership Perspectives

Ming Hsieh, CEO of Fulgent, is optimistic about the deal. He believes it will accelerate growth and improve service quality. The CEOs of Bako and StrataDx are also enthusiastic, seeing the merger as a way to better serve their clients.

Risks and Challenges

While this deal represents a major step forward for Fulgent, it also comes with risks. There is no guarantee the deal will be finalized, and even if it is, success is not assured.